1. Baseline neutrophil-to-lymphocyte ratio and PD-L1 expression level or LDH value may predict outcome of patients with high PD-L1 advanced non-small cell lung cancer treated with first-line pembrolizumab. (January 2020) Authors: Banna, G.; Signorelli, D.; Metro, G.; Galetta, D.; De Toma, A.; Cantale, O.; Banini, M.; Friedlaender, A.; Pizzutillo, P.; Garassino, M.; Addeo, A. Journal: Lung cancer Issue: Volume 139(2020)Supplement 1 Page Start: S58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0478 SEROLOGICAL AUTOIMMUNITY IN PATIENTS WITH RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS: CORRELATION WITH SEVERITY AND TREATMENT. (13th June 2020) Authors: Campochiaro, C.; Tomelleri, A.; Ferrara, R.; Lazzari, C.; De Luca, G.; Signorelli, D.; Bulotta, A.; Gregorc, V.; Garassino, M.; Dagna, L. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 836 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. (May 2019) Authors: Proto, C.; Ferrara, R.; Signorelli, D.; Lo Russo, G.; Galli, G.; Imbimbo, M.; Prelaj, A.; Zilembo, N.; Ganzinelli, M.; Pallavicini, L.M.; De Simone, I.; Colombo, M.P.; Sica, A.; Torri, V.; Garassino, M.C. Journal: Cancer treatment reviews Issue: Volume 75(2019) Page Start: 39 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗